logo-loader
viewTyraTech, Inc.

Fresh start for Tyratech with new strategic focus on animal health

Bruno Jactel, chief executive of Tyratech Inc. (LON:TYR LON:TYRU) chats to Proactive's Andrew Scott about the proposed sale of Vamousse to Alliance Pharma plc (AIM: APH).

It's for an initial cash consideration of $13mln with Tyratech potentially being entitled to further performance-based payments of up to $4.5 million.

Jactel also outlines their new strategic focus on animal health and the plans they've got to maximise opportunities in what's a $6bln market.

Quick facts: TyraTech, Inc.

Price: - -

AIM:TYR
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: De Grey Mining strikes wide gold mineralisation zone in...

De Grey Mining Ltd (ASX:DEG) executive chairman Simon Lill updates Proactive on new gold mineralisation defined at the Buckle prospect in W.A.’s Pilbara region, after first drilling. RC drilling is now planned to commence in February to determine further resource potential of the exciting new...

52 minutes ago

2 min read